AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024
The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
- The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
- Affinity tuned AIC100 is expected to selectively bind and kill tumor cells expressing cell surface ICAM-1 while sparing healthy cells.
- “We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types.
- “This promising preclinical data presented at AACR 2024 suggest that AIC100 could be a potential new option for patients with these ICAM-1-positive tumors.”